glp 1 and chronic kidney disease Real-World Evidence for GLP-1 Receptor Agonists Across the CKD Spectrum – AJKD Blog Full article: Cardiorenal protective effects

The studys authors said more research is needed to fully understand and confirm the risk of NAION among people taking semaglutide drugs

GLP-1 agonists reduce appetite , which contributes to their role in weight management

( n ) Dot plots show the ELISA assessment of serum anti-dsDNA antibodies titers

Approximately 15-40% of individuals diagnosed with IBD and an additional 20-40% are estimated to be obese and overweight respectively ( Table 1 )

The real opportunity is the next wave: triple agonists, oral GLP-1 drugs, amylin combinations, glucagon-based metabolic therapies, and precision obesity treatment models

Brett Florie, Hydration Room offers expert-formulated IV therapy